ESMO 2022 Conference Coverage
Breast
ESMO 2022 Conference Coverage
ESMO 2022 Updates on mTNBC
FEATURING
Lisa Carey
- 1,482 views
- October 28, 2022
- 5
ESMO 2022 Conference Coverage
ESMO 2022 on the First Results From the BELLINI Trial: Nivo & Ipi in Early Stage TNBC With TILs
FEATURING
Marleen Kok
- 45 views
- October 18, 2022
ESMO 2022 Conference Coverage
ESMO 2022 on DESTINY-Breast04 Patient-Reported Outcomes: T-DXd vs. TPC in HER2-Low mBC
FEATURING
Naoto Ueno
- 480 views
- October 3, 2022
- 2
ESMO 2022 Conference Coverage
Lecture Summary - ESMO 2022 on Primary Endpoint Results of the Randomized Phase 2 SYNERGY Trial: 1L Chemo-IO of Durvalumab, Paclitaxel, and Carboplatin +/- Anti-CD73 Antibody Oleclumab in Advanced or Metastatic TNBC
FEATURING
Laurence Buisseret
- 18 views
- September 27, 2022
ESMO 2022 Conference Coverage
ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates
FEATURING
Hope Rugo,
Joyce O'Shaughnessy
- 5,912 views
- September 23, 2022
- 32
ESMO 2022 Conference Coverage
ESMO 2022 on HER2-Low Inflammatory Breast Cancer: Clinicopathologic Features and Prognostic Implications
FEATURING
Paolo Tarantino
- 424 views
- September 21, 2022
- 1
ESMO 2022 Conference Coverage
ESMO 2022 on Adjuvant Endocrine Therapy for BC: Who Needs More Than 5 Years, Which Regimen, and What Duration Beyond 5 Years?
FEATURING
Evandro de Azambuja
- 2,482 views
- September 15, 2022
- 12
ESMO 2022 Conference Coverage
ESMO 2022 on the DAISY Trial: Antitumor Activity of T-DXd in Patients With mBC and Brain Metastases
FEATURING
Nicolas Epaillard
- 1,300 views
- September 14, 2022
- 1